Comparison of hepatic resection and transarterial chemoembolization for solitary hepatocellular carcinoma

Figure 1 One-, 3-, and 5-year overall survival of patients in the liver resection group was 86. 2%, 62.8%, and 44.0%, respectively, and 88.3%, 59.8%, and 40.6%, respectively, for patients in the transarterial chemoembolization group. The long-term outcomes of the two groups were similar. TACE: Transarterial chemoembolization.

Figure 2 Long-term overall survival in the liver resection group was significantly better than that in the transarterial chemoembolization group for solitary hepatocellular carcinomas with a diameter of no more than 6 cm. The survival benefit in the liver resection group increased further after 3 years. HCC: Hepatocellular carcinoma; TACE: Transarterial chemoembolization.

Figure 3 Survival benefit that was observed in the liver resection group was no longer present when the diameter of the solitary hepatocellular carcinoma was less than or equal to 7 cm. HCC: Hepatocellular carcinoma; TACE: Transarterial chemoembolization.

Figure 4 Liver resection group. A: Liver resection group did not show any survival benefit when the diameter of the solitary hepatocellular carcinoma was less than or equal to 8 cm; B: Liver resection group did not show any advantage with respect to long-term survival when the diameter of the solitary hepatocellular carcinomas was greater than 6 cm. HCC: Hepatocellular carcinoma; TACE: Transarterial chemoembolization.